Alemtuzumab is a medication used to treat relapsing-remitting multiple sclerosis (MS). It works by targeting specific cells in the immune system that are involved in causing damage to the nervous system in MS patients.

Cladribine is a medication that helps reduce inflammation in multiple sclerosis by decreasing the number of certain white blood cells that contribute to the immune system attack on nerve cells.

Ocrelizumab is a medication that targets specific B-cells in the immune system. It helps reduce inflammation and nerve damage in people with relapsing-remitting multiple sclerosis.

Autologous Hematopoietic Stem Cell Transplantation (HSCT) is a therapeutic procedure where a patient’s own blood-forming stem cells are collected, stored, and then returned to their body after receiving treatments to suppress their immune system. This procedure aims to “reset” the immune system to stop it from attacking the nervous system.

Multiple Sclerosis – A chronic neurological condition where the immune system attacks the protective covering (myelin) of nerve fibers in the central nervous system. This damage disrupts communication between the brain and the rest of the body, causing a range of symptoms that can include problems with vision, balance, muscle control, and other basic body functions. The disease typically progresses in a pattern of relapses and remissions, where symptoms may come and go or gradually worsen over time. Multiple sclerosis can affect different people in different ways, with symptoms varying in type and severity. The condition most commonly appears between ages 20 and 40, and affects the brain, spinal cord, and optic nerves.